Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and Non-clonal disorders

Seminars in Hematology

Volumn 49, Issue 2, 2012, Pages 128-137

  Gotlib, Jason ^a   Akin, Cem ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOKINE; DASATINIB; DOXORUBICIN; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; MIDOSTAURIN; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; SORAFENIB; STEM CELL FACTOR; SUNITINIB; VINCRISTINE;

5' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC DISEASE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL ACTIVITY; CELL AGGREGATION; CELL CONTACT; CELL COUNT; CELL FUNCTION; CELL INFILTRATION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHROMOSOME 4Q; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME REGULATION; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; EVENT FREE SURVIVAL; EXPERIMENTAL MODEL; FIP1L1 PDGFRA GENE; FOLLICULAR LYMPHOMA; GAIN OF FUNCTION MUTATION; GENE FUSION; GENE IDENTIFICATION; GENE REARRANGEMENT; GENETIC MARKER; GENETIC VARIABILITY; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HOMEOSTASIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNE RESPONSE; INFLAMMATION; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; LYMPHOMA; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; MAST CELL; MYELOFIBROSIS; MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC MASTOCYTOSIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANIMALS; CHRONIC DISEASE; EOSINOPHILS; GENE EXPRESSION REGULATION, LEUKEMIC; HOMEOSTASIS; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5; MAST CELLS; MASTOCYTOSIS; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; STEM CELL FACTOR;

EID: 84858790498     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.01.007     Document Type: Article

References (98)

1. Stone K.D., Prussin C., Metcalfe D.D. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2010, 125:S73-S80.
2. Denburg J.A., Telizyn S., Messner H., et al. Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor. Blood 1985, 66:312-318.
3. Kitamura Y., Oboki K., Ito A. Molecular mechanisms of mast cell development. Immunol Allergy Clin North Am 2006, 26:387-405.
4. + pluripotent progenitor cells. J Immunol 1992, 148:772-777.
5. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-956.
6. Gauvreau G.M., Ellis A.K., Denburg J.A. Haemopoietic processes in allergic disease: eosinophil/basophil development. Clin Exp Allergy 2009, 39:1297-1306.
7. + progenitor cells. J Immunol 2003, 170:537-547.
8. Rothenberg M.E., Hogan S.P. The eosinophil. Annu Rev Immunol 2006, 24:147-174.
9. Minai-Fleminger Y., Levi-Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm Res 2009, 58:631-638.
10. Abonia J.P., Blanchard C., Butz B.B., et al. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010, 126:140-149.
11. Piazuelo M.B., Camargo M.C., Mera R.M., et al. Eosinophils and mast cells in chronic gastritis: possible implications in carcinogenesis. Hum Pathol 2008, 39:1360-1369.
12. Caruso R.A., Fedele F., Zuccala V., Fracassi M.G., Venuti A. Mast cell and eosinophil interaction in gastric carcinomas: ultrastructural observations. Anticancer Res 2007, 27:391-394.
13. Anthony R.M., Rutitzky L.I., Urban J.F., Stadecker M.J., Gause W.C. Protective immune mechanisms in helminth infection. Nat Rev Immunol 2007, 7:975-987.
14. Jeziorska M., Haboubi N., Schofield P., Woolley D.E. Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique. J Pathol 2001, 194:484-492.
15. Ellyard J.I., Simson L., Bezos A., Johnston K., Freeman C., Parish C.R. Eotaxin selectively binds heparin. An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. J Biol Chem 2007, 282:15238-15247.
16. Shakoory B., Fitzgerald S.M., Lee S.A., Chi D.S., Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004, 24:271-281.
17. Takafuji S., Tadokoro K., Ito K., Nakagawa T. Release of granule proteins from human eosinophils stimulated with mast-cell mediators. Allergy 1998, 53:951-956.
18. Wong C.K., Ng S.S., Lun S.W., Cao J., Lam C.W. Signalling mechanisms regulating the activation of human eosinophils by mast-cell-derived chymase: implications for mast cell-eosinophil interaction in allergic inflammation. Immunology 2009, 126:579-587.
19. Pang L., Nie M., Corbett L., Sutcliffe A., Knox A.J. Mast cell beta-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities. J Immunol 2006, 176:3788-3795.
20. Hartman M., Piliponsky A.M., Temkin V., Levi-Schaffer F. Human peripheral blood eosinophils express stem cell factor. Blood 2001, 97:1086-1091.
21. Hudson S.A., Herrmann H., Du J., et al. Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J Clin Immunol 2011, 31:1045-1053.
22. Nutku E., Aizawa H., Hudson S.A., Bochner B.S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003, 101:5014-5020.
23. Yokoi H., Choi O.H., Hubbard W., et al. Inhibition of FcepsilonRI-dependent mediator release and calcium flux from human mast cells by sialic acid-binding immunoglobulin-like lectin 8 engagement. J Allergy Clin Immunol 2008, 121:499-505.
24. Minai-Fleminger Y., Elishmereni M., Vita F., et al. Ultrastructural evidence for human mast cell-eosinophil interactions in vitro. Cell Tissue Res 2010, 341:405-415.
25. Glimelius I., Rubin J., Rostgaard K., et al. Predictors of histology, tissue eosinophilia and mast cell infiltration in Hodgkin's lymphoma-a population-based study. Eur J Haematol 2011, 87:208-216.
26. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
27. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096.
28. Bain B.J., Gilliland D.G., Horny H.-P., et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1. World Health Organization classification of tumours. pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008, 68-73. IARC Press, Lyon, France. S. Swerdlow, N.L. Harris, H. Stein, E.S. Jaffe, J. Theile, J.W. Vardiman (Eds.).
29. Chusid M.J., Dale D.C., West B.C., et al. The hypereosinophilic syndrome. Analysis of fourteen cases with review of the literature. Medicine 1975, 54:1-27.
30. Gotlib J., Cools J. Five years since the discovery of the FIPL1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008, 22:1999-2010.
31. Spry C.J., Davies J., Tai P.C., et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983, 52:1-22.
32. Lefebvre C., Bletry O., Degoulet P., et al. Prognostic factors of hypereosinophilic syndrome. Study of 40 cases. Ann Med Interne (Paris) 1989, 140:253-257.
33. Flaum M.A., Schooley R.T., Fauci A.S., et al. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. Blood 1981, 58:1012-1020.
34. Fauci A.S., Harley J.B., Roberts W.C., et al. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982, 97:78-92.
35. Weller P.F., Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood 1994, 83:2759-2779.
36. Schaller J.L., Burkland G.A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001, 7:3-9.
37. Gleich G.J., Leiferman K.M., Pardanani A., et al. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002, 359:1577-1578.
38. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660-4666.
39. Pardanani A., Brockman S.R., Paternoster S.F., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004, 104:3038-3045.
40. Horny H.P., Akin C., Metcalfe D.D., et al. Mastocytosis. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 53-63. IARC Press, Lyon, France. S. Swerdlow, E. Campo, N. Lee Harris (Eds.).
41. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
42. Sotlar K., Fridrich C., Mall A., et al. Detection of c-kit point mutation Asp-816 Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002, 26:979-984.
43. Robyn J., Lemery S., McCoy J.P., et al. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006, 132:286-292.
44. Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007, 120:680-687.
45. Buitenhuis M., Verhagen L.P., Cools J., Coffer P.J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007, 67:3759-3766.
46. Cools J., Stover E.H., Boulton C.L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell 2003, 3:459-469.
47. Yamada Y., Rothenberg M.E., Lee A.W., et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006, 107:4071-4079.
48. Burgstaller S., Kreil S., Waghorn K., Metzgeroth G., Preudhomme C., Zoi K., et al. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 2007, 21:2428-2432.
49. Yamada Y., Sanchez-Aguilera A., Brandt E.B., et al. FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. Blood 2008, 112:2500-2507.
50. Pardanani A., Lim K.H., Lasho T.L., et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood 2009, 114:3769-3772.
51. Böhm A., Födinger M., Wimazal F., et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007, 120:192-199.
52. Wimazal F., Germing U., Kundi M., et al. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer 2010, 116:2372-2381.
53. Matsushima T., Handa H., Yokohama A., et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003, 101:3386-3390.
54. Utsunomiya A., Ishida T., Inagaki A., et al. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res 2007, 31:915-920.
55. Inagaki A., Ishida T., Ishii T., et al. Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer 2006, 118:3054-3061.
56. Ionescu M.A., Rivet J., Daneshpouy M., et al. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol 2005, 5:32-39.
57. Molin D., Fischer M., Xiang Z., et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br J Haematol 2001, 11:616-623.
58. Fischer M., Juremalm M., Olsson N., et al. Expression of CCL5/rantes by Hodgkin and Reed-Sternberg cells and its possible role in the recruitement of mast cells into lymhpomatous tissue. Int J Cancer 2003, 107:197-201.
59. Molin D., Edström A., Glimelius I., et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol 2002, 119:122-124.
60. Canioni D., Deau-Fischer B., Taupin P., et al. Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS One 2009, 4:e6341.
61. von Wasielewski R., Seth S., Franklin J., et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood 2000, 95:1207-1213.
62. Enblad G., Sundstrom C., Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993, 11:187-193.
63. Hedström G., Berglund M., Molin D., et al. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2007, 138:68-71.
64. Taskinen M., Karjalainen-Lindsberg M.L., Leppä S. Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. Blood 2008, 111:4664-4667.
65. Longley B.J., Tyrrell L., Lu S.Z., et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996, 12:312-314.
66. Longley B.J., Metcalfe D.D., Tharp M., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999, 96:1609-1614.
67. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31:686-692.
68. Zermati Y., De Sepulveda P., Feger F., et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene 2003, 22:660-664.
69. Akin C., Fumo G., Yavuz A.S., et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103:3222-3225.
70. Gotlib J., DeAngelo D.J., George T.I., et al. KIT inhibitor Midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of a fully accrued phase II trial. Blood (ASH Annual Meeting Abstracts) 2010, 116:316. (2010).
71. Verstovsek S., Tefferi A., Cortes J., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14:3906-3915.
72. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., et al. Response to interferon a-2b in a patient with systemic mastocytosis. N Engl J Med 1992, 326:619-623.
73. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., Metcalfe D.D. Treatment of three patients with systemic mastocytosis with interferon alfa-2b. Leuk Lymphoma 1996, 22:501-508.
74. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br J Dermatol 1998, 138:489-495.
75. Casassus P., Caillat-Vigneron N., Martin A., et al. Treatment of adult systemic mastocytosis with interferon-a: Results of a multicentre phase II trial on 20 patients. Br J Haematol 2002, 119:1090-1097.
76. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., et al. Response to therapy with interferon a-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004, 28:249-257.
77. Tefferi A., Li C.Y., Butterfield J.H., et al. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001, 344:307-309.
78. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 2003, 102:427-436.
79. Lortholary O., Vargaftig J., Feger F., et al. Efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 33 patients. Blood (ASH Annual Meeting Abstracts) 2004, 104:661.
80. Pardanani A., Hoffbrand A.V., Butterfield J.H., et al. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004, 28:127-131.
81. Hermine O., Hirsh I., Damaj G., et al. Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients. ASH Annual Meeting Abstracts 2010, 116:1982.
82. Lim K.H., Pardanani A., Butterfield J.H., Li C.Y., Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009, 84:790-794.
83. Baccarani M., Cilloni D., Rondoni M., et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92:1173-1179.
84. Jovanovic J.V., Score J., Waghorn K., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635-4640.
85. Klion A.D., Robyn J., Akin C., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004, 103:473-478.
86. Helbig G., Stella-Hołowiecka B., Majewski M., et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008, 141:200-204.
87. Klion A.D., Robyn J., Maric I., et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007, 110:3552-3556.
88. Von Bubnoff N., Sandherr M., Schlimok G., et al. Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFRalpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2004, 19:286-287.
89. Ohnishi H., Kandabashi K., Maeda Y., et al. Chronic eosinophilic leukaemia with FIP1L1-PDGFRA fusion and T6741 mutation that evolved from Langerhans cell histiocytosis with eosinophilia after chemotherapy. Br J Haematol 2006, 134:547-549.
90. Lierman E., Michaux L., Beullens E., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
91. Simon D., Salemi S., Yousefi S., et al. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008, 121:1054-1056.
92. Lierman E., Folens C., Stover E.H., et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006, 108:1374-1376.
93. Stover E.H., Chen J., Lee B.H., et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005, 106:3206-3213.
94. von Bubnoff N., Gorantla S.P., Thone S., et al. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 2006, 107:4970-4971.
95. Cross D.M., Cross N.C., Burgstaller S., et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007, 109:61-64.
96. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010, 41:461-476.
97. Mayeur-Rousse C., Sorel N., Voldoiref M., et al. Unique association of systemic mastocytosis and myeloid/lymphoid neoplasm in blast crisis with abnormality of FGFR1 gene. Leuk Res 2012, 36:377-381.
98. Lahortiga I., Akin C., Cools J., et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica 2008, 93:49-56.